Biology, biomarkers, and breakthrough therapies—ushering in a new era of hope for Alzheimer’s disease

1. Describe the current understanding of the biological mechanisms, natural history, symptoms and signs of Alzheimer’s disease.
2. Explain the AT(N) framework in diagnosing and staging Alzheimer’s disease.
3. Discuss cerebrospinal fluid, PET imaging, and blood-based biomarkers, and assess their clinical utility.
4. Discuss recent advances in anti-amyloid monoclonal antibodies disease modifying therapies
5. Evaluate the implications of biomarker-driven diagnosis and therapy for clinical practice, patient care, and health systems.

Accreditation:

Saint Louis University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Credit Designation:

Saint Louis University School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Saint Louis University School of Medicine will provide Other learner certificates (APPs, nurses, and other types of learners).  The certificate will state that the activity was designated for 1.0 AMA PRA Category 1 Credits™.  Follow your board's requirements for reciprocal CE credits.

Mitigation of Relevant Financial Relationships

Saint Louis University School of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.